Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

730.99 -16.02 (-2.14%)
Streaming Delayed Price Updated: 1:24 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.
Via The Motley Fool
Topics Government
Exposures Political
3 Unstoppable Stocks That You Can Buy and Hold for Years
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight. 
Via Benzinga
Topics ETFs Government
Exposures Political
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries. 
Via Benzinga
Topics Government
Exposures Political
CVS Health Appoints New CFO, Chief Medical Officer: Retail Sentiment Soars
The company said that Brian Newman has been named chief financial officer, effective April 21, succeeding current CFO Tom Cowhey. 
Via Stocktwits
Blackstone Stock Gets Price Target Cuts From Citi, Barclays, Piper Sandler — Retail Remains Bearish
Citi analyst Christopher Allen lowered the firm's price target on Blackstone to $137 from $190 and kept a ‘Neutral' rating on the shares. 
Via Stocktwits
Topics Economy Government World Trade
Exposures Economy Political Tariff
Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population 
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected. 
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major... 
Via Benzinga
Topics Government
Exposures Political
Eli Lilly: What Lepodisiran Could Mean For This Big Pharma Play
Lepodisiran is being developed by biotech giant Eli Lilly & Co. Here’s the tale of this new drug, how it could help millions, and how this furthers the “less-is-more” strategy that will make Lilly the... 
Via Talk Markets
Topics Stocks / Equities
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Topics Economy Intellectual Property
Exposures Economy Intellectual Property
3 Growth ETFs to Buy With $500 and Hold
It doesn't take deep pockets to build a diversified growth portfolio. 
Via The Motley Fool
Topics ETFs
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. 
Via Investor's Business Daily
Topics Government
Exposures Political
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert
U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs. 
Via Benzinga
Topics Government
Exposures Political
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption
On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 
Via Stocktwits
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co. 
Via Benzinga
Stock Market Sell-Off: The 9 Best Stocks to Buy Now in April (2025)
Via The Motley Fool
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Why April Could Be a Huge Month for Eli Lilly Stock
Via The Motley Fool
Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?
Via The Motley Fool
Topics Economy
Exposures Economy
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Why Major Pharmaceutical Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Why Hims & Hers Health Stock Soared Tuesday
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.